Quercetin mitigates doxorubicin-induced cardiotoxicity in vitro and in vivo by activating the HO-1/PGC-1α pathway, reducing iron accumulation, and inhibiting ferroptosis and oxidative stress.
Myocardial injury caused by Doxorubicin has limited its clinical application. Our research has demonstrated that doxorubicin induces various forms of cell death, oxidative stress, and metabolic abnormalities. We have confirmed, through both in vitro and in vivo studies, that apoptosis, iron overload, inflammatory responses, and arachidonic acid metabolism contribute to doxorubicin’s cardiotoxic effects. Treatment with quercetin effectively reduces iron accumulation and preserves mitochondrial structural integrity by inhibiting oxidative stress and inflammatory responses. Using molecular docking and surface plasmon resonance (SPR) techniques, our study suggests that quercetin activates the HO-1/PGC-1α pathway, which may involve downregulation of ALOX5 expression, thereby alleviating oxidative stress, inhibiting iron-dependent lipid peroxidation and ferroptosis-like changes, mitigating inflammatory responses, and modulating arachidonic acid metabolism. Additionally, quercetin enhances energy availability and supports mitochondrial function. We propose quercetin, a promising active compound derived from traditional Chinese medicine, as a potential mitigator of doxorubicin-induced cardiotoxicity. Graphical Abstract
Duan et al. (2026) studied Doxorubicin-induced cardiotoxicity. Quercetin was evaluated. Quercetin mitigates doxorubicin-induced cardiotoxicity in vitro and in vivo by activating the HO-1/PGC-1α pathway, reducing iron accumulation, and inhibiting ferroptosis and oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: